Fibrosis is a widespread reparative or reactive process resulting in the accumulation of excess fibrous tissue. This biological process is involved in a large number of clinical indications with significant unmet medical need. RXi’s lead clinical candidate, RXI-109, is an sd-rxRNA compound that targets connective tissue growth factor (CTGF), a key regulatory component of fibrosis and scar formation that plays a key role in tissue regeneration and repair. and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial in ophthalmology.
RXi's consumer health compounds are intended to affect the appearance of the skin. As a consumer health product, no preventative or therapeutic claims can be made. However, these compounds may be developed more rapidly than therapeutics and, therefore, the path to the market may be shorter and less expensive. RXi has selected two compounds for cosmetic product development based on its proprietary self-delivering RNAi (sd-rxRNA) platform. These candidates are part of RXi's partnering and business development initiative providing multiple development opportunities for non-therapeutic skin health.
Warts are extremely common, being experienced by most people at some time during their lives. Although most warts will spontaneously disappear without treatment, treatment of these lesions is sought to prevent recurrence. Treatment of warts is complicated by low success rates, prolonged duration of therapy, and the potential for recurrence. Samcyprone™ is being studied for the treatment of cutaneous warts, benign epidermal tumors caused by human papillomaviruses (HPVs) in a Phase 2 clinical trial.